Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion, RO7247669
BO44157
Phase 2 small_molecule active
Quick answer
Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion, RO7247669 for Previously Untreated Locally Advanced or Metastatic Urothelial Cancer is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active